Dynavax shares surge despite going-concern warning; 4-Antibody to partner with Boehringer; Tekmira buoyed by collaboration;

@FierceBiotech: Quintiles sheds CRO label. Report | Follow @FierceBiotech

@JohnCFierce: Venture funding for life sciences $1.9B in 4Q, flat from the 3Q, says VentureDeal. But biotech VC rounds swell. Follow @JohnCFierce

> The auditors for Dynavax Technologies say that the company's financial position has created doubts about the developer's ability to continue as a going concern. But Dynavax responded by saying that its completed enrollment in a big trial of its hepatitis B vaccine Heplisav and is on track to file for an approval in the third quarter of 2011-six months ahead of schedule. Investors looked past the auditor's warning and drove up the value of the company's shares by 10 percent this morning. Dynavax reported $36.7 million in unrestricted cash and cash equivalents at December 31, 2009. Dynavax release | Report

> Switzerland's 4-Antibody AG announced a collaboration with Boehringer Ingelheim today that could be worth up to 177.5 million euros in unspecified upfront fees and milestones. The two will partner on the development of new antibodies. 4-Antibody release

> Shares of Tekmira surged 20 percent this morning after the company announced plans to collaborate with Pfizer on using its delivery technology for the pharma company's gene silencing therapies. Tekmira release

> Yesterday evening the execs at Sequenom declined to offer their investors financial guidance for the year ahead, and they responded by driving down the value of the company's stock by 17 percent. Sequenom shares plunged last year after the company acknowledged that clinical data for one of its gene tests were unreliable. Report

> Forma Therapeutics is partnering with the Leukemia and Lymphoma Society to develop new drugs for a lymphoma target. Story

And Finally.... ED is a strong predictor of death from all causes and of heart attack, stroke and heart failure in men with cardiovascular disease, German researchers reported in Circulation: Journal of the American Heart Association. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.